Atrial Fibrillation: Goals of Therapy and Management Strategies to Achieve the Goals

Medical Clinics of North America

Volumn 92, Issue 1, 2008, Pages 217-235

  Padanilam, Benzy J ^a   Prystowsky, Eric N ^a  

^a Care Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CLOPIDOGREL; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; VERAPAMIL; WARFARIN; XIMELAGATRAN;

ANXIETY; ARTIFICIAL HEART PACEMAKER; BLEEDING; CARDIOMYOPATHY; CARDIOVERSION; CATHETER ABLATION; CLINICAL TRIAL; DISEASE CLASSIFICATION; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EXCRETION; DRUG MEGADOSE; DYSPNEA; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART HEMODYNAMICS; HEART PALPITATION; HUMAN; LABORATORY TEST; LIVER TOXICITY; LOW DRUG DOSE; LUNG DISEASE; META ANALYSIS; NEUROLOGIC DISEASE; OPTIC NERVE DISEASE; PATIENT CARE; PHYSICAL EXAMINATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QT PROLONGATION; RADIOFREQUENCY ABLATION; REVIEW; RISK FACTOR; RISK REDUCTION; STROKE; SUSTAINED RELEASE FORMULATION; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TACHYCARDIA; THORAX PAIN; THROMBOEMBOLISM; THYROID DISEASE; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT; WOLFF PARKINSON WHITE SYNDROME;

ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; ELECTRIC COUNTERSHOCK; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK ASSESSMENT; THROMBOEMBOLISM;

EID: 36448990820     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2007.08.006     Document Type: Review

References (70)

1. Benjamin E.J., Wolf P.A., D'Agostino R.B., et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98 10 (1998) 946-952
2. Heppell R.M., Berkin K.E., McLenachan J.M., et al. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart 77 5 (1997) 407-411
3. Conway D.S., Pearce L.A., Chin B.S., et al. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 107 25 (2003) 3141-3145
4. Wolf P.A., Abbott R.D., and Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22 8 (1991) 983-988
5. Lin H.J., Wolf P.A., Kelly-Hayes M., et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 27 10 (1996) 1760-1764
6. Stafford R.S., and Singer D.E. National patterns of warfarin use in atrial fibrillation. Arch Intern Med 156 22 (1996) 2537-2541
7. Waldo A.L., Becker R.C., Tapson V.F., et al. NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 46 9 (2005) 1729-1736
8. Wyse D.G., Waldo A.L., DiMarco J.P., et al., Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 23 (2002) 1825-1833
9. Van Gelder I.C., Hagens V.E., Bosker H.A., et al., Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347 23 (2002) 1834-1840
10. Shinbane J.S., Wood M.A., Jensen D.N., et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 29 4 (1997) 709-715
11. Ozcan C., Jahangir A., Friedman P.A., et al. Significant effects of atrioventricular node ablation and pacemaker implantation on left ventricular function and long-term survival in patients with atrial fibrillation and left ventricular dysfunction. Am J Cardiol 92 1 (2003) 33-37
12. Nerheim P., Birger-Botkin S., Piracha L., et al. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 110 3 (2004) 247-252
13. Padanilam B.J., and Prystowsky E.N. New antiarrhythmic agents for the prevention and treatment of atrial fibrillation. J Cardiovasc Electrophysiol 17 (2006) S62-S66
14. Corley S.D., Epstein A.E., DiMarco J.P., et al., AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109 12 (2004) 1509-1513
15. Pappone C., Rosanio S., Augello G., et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 42 2 (2003) 185-197
16. Wazni O.M., Marrouche N.F., Martin D.O., et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 293 21 (2005) 2634-2640
17. Feinberg W.M., Blackshear J.L., Laupacis A., et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 155 5 (1995) 469-473
18. Wolf P.A., Benjamin E.J., Belanger A.J., et al. Secular trends in the prevalence of atrial fibrillation: the Framingham Study. Am Heart J 131 4 (1996) 790-795
19. Anonymous. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154 13 (1994) 1449-1457
20. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285 22 (2001) 2864-2870
21. Fuster V., Ryden L.E., Cannom D.S., et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines, European Society of Cardiology Committee for Practice Guidelines, European Heart Rhythm Association, Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114 7 (2006) e257-e354
22. Hart R.G., and Halperin J.L. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 131 9 (1999) 688-695
23. Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 429S-456S
24. Hylek E.M., Go A.S., Chang Y., et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349 11 (2003) 1019-1026
25. Hart R.G., Halperin J.L., Pearce L.A., et al., Stroke Prevention in Atrial Fibrillation Investigators. Lessons from the stroke prevention in atrial fibrillation trials. Ann Intern Med 138 10 (2003) 831-838
26. Friberg J., Scharling H., Gadsboll N., et al., Copenhagen City Heart Study. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol 94 7 (2004) 889-894
27. Hylek E.M., Evans-Molina C., Shea C., et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115 21 (2007) 2689-2696
28. Connolly S., Pogue J., Hart R., et al., ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367 9526 (2006) 1903-1912
29. Kaul S., Diamond G.A., and Weintraub W.S. Trials and tribulations of non-inferiority: the ximelagatran experience. J Am Coll Cardiol 46 11 (2005) 1986-1995
30. Blackshear J.L., Johnson W.D., Odell J.A., et al. Thoracoscopic extracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation. J Am Coll Cardiol 42 7 (2003) 1249-1252
31. Ostermayer S.H., Reisman M., Kramer P.H., et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol 46 1 (2005) 9-14
32. Arnold A.Z., Mick M.J., Mazurek R.P., et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 19 4 (1992) 851-855
33. Klein A.L., Grimm R.A., Murray R.D., et al., Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344 19 (2001) 1411-1420
34. Stellbrink C., Nixdorff U., Hofmann T., et al., ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 109 8 (2004) 997-1003
35. Carlsson J., Miketic S., Windeler J., et al., STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 41 10 (2003) 1690-1696
36. Hohnloser S.H., Kuck K.H., and Lilienthal J. Rhythm or rate control in atrial fibrillation-pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. Lancet 356 9244 (2000) 1789-1794
37. Opolski G., Torbicki A., Kosior D.A., et al., Investigators of the Polish How to Treat Chronic Atrial Fibrillation Study. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 126 2 (2004) 476-486
38. Hsu L.F., Jais P., Sanders P., et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351 23 (2004) 2373-2383
39. Gentlesk P.J., Sauer W.H., Gerstenfeld E.P., et al. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol 18 1 (2007) 9-14
40. Deedwania P.C., Singh B.N., Ellenbogen K., et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 98 23 (1998) 2574-2579
41. Pedersen O.D., Bagger H., Keller N., et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 104 3 (2001) 292-296
42. Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Am Heart J 14 (2002) 597-607
43. Cooper H.A., Bloomfield D.A., Bush D.E., et al., AFFIRM Study Investigators. Relation between achieved heart rate and outcomes in patients with atrial fibrillation (from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study). Am J Cardiol 93 (2004) 1247-1253
44. Prystowsky E.N. Assessment of rhythm and rate control in patients with atrial fibrillation. J Cardiovasc Electrophysiol 17 2 (2006) S7-S10
45. Bjerregaard P., Bailey W.B., and Robinson S.E. Rate control in patients with chronic atrial fibrillation. Am J Cardiol 93 3 (2004) 329-332
46. Meng F., Yoshikawa T., Baba A., et al. Beta-blockers are effective in congestive heart failure patients with atrial fibrillation. J Card Fail 9 5 (2003) 398-403
47. Khand A.U., Rankin A.C., Martin W., et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?. J Am Coll Cardiol 42 11 (2003) 1944-1951
48. Scardi S., Humar F., Pandullo C., et al. Oral clonidine for heart rate control in chronic atrial fibrillation. Lancet 341 8854 (1993) 1211-1212
49. Wood M.A., Brown-Mahoney C., Kay G.N., et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation 101 10 (2000) 1138-1144
50. Weerasooriya R., Davis M., Powell A., et al. The Australian intervention randomized control of rate in atrial fibrillation trial (AIRCRAFT). J Am Coll Cardiol 41 10 (2003) 1697-1702
51. Wilkoff B.L., Cook J.R., Epstein A.E., et al., Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the dual chamber and VVI implantable defibrillator (DAVID) trial. JAMA 288 24 (2002) 3115-3123
52. Simantirakis E.N., Vardakis K.E., Kochiadakis G.E., et al. Left ventricular mechanics during right ventricular apical or left ventricular-based pacing in patients with chronic atrial fibrillation after atrioventricular junction ablation. J Am Coll Cardiol 43 6 (2004) 1013-1018
53. Garrigue S., Bordachar P., Reuter S., et al. Comparison of permanent left ventricular and biventricular pacing in patients with heart failure and chronic atrial fibrillation: prospective haemodynamic study. Heart 87 6 (2002) 529-534
54. Doshi R.N., Daoud E.G., Fellows C., et al., PAVE Study Group. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 16 11 (2005) 1160-1165
55. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321 (1989) 406-412
56. Lafuente-Lafuente C., Mouly S., Longas-Tejero M.A., et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. [review] [63 refs]. Arch Intern Med 166 7 (2006) 719-728
57. Roden D.M., Woosley R.L., and Primm R.K. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 111 6 (1986) 1088-1093
58. Roy D., Talajic M., Dorian P., et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 342 13 (2000) 913-920
59. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med 356 9 (2007) 935-941
60. Alboni P., Botto G.L., Baldi N., et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 351 23 (2004) 2384-2391
61. Haissaguerre M., Jais P., Shah D.C., et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339 10 (1998) 659-666
62. Haissaguerre M., Jais P., Shah D.C., et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation 101 12 (2000) 1409-1417
63. Padanilam B.J., and Prystowsky E.N. Should ablation be first-line therapy and for whom: The antagonist position. Circulation 112 8 (2005) 1223-1229
64. Cox J., Schuessler R., and Lappas D. An 81/2-year clinical experience with surgery for atrial fibrillation. Ann Surg 224 3 (1996) 267-275
65. Hocini M., Sanders P., Deisenhofer I., et al. Reverse remodeling of sinus node function after catheter ablation of atrial fibrillation in patients with prolonged sinus pauses. Circulation 108 10 (2003) 1172-1175
66. McKeown P.P., and Gutterman D. Executive summary: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest 128 2 Suppl (2005) 1S-5S
67. Stamou S.C., Hill P.C., Dangas G., et al. Stroke after coronary artery bypass: incidence, predictors, and clinical outcome. Stroke 32 7 (2001) 1508-1513
68. Taylor G.J., Malik S.A., Colliver J.A., et al. Usefulness of atrial fibrillation as a predictor of stroke after isolated coronary artery bypass grafting. Am J Cardiol 60 10 (1987) 905-907
69. Crystal E., Connolly S.J., Sleik K., et al. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 106 1 (2002) 75-80
70. Klein G.J., Bashore T.M., Sellers T.D., et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med 301 20 (1979) 1080-1085